Safety and Efficacy of Targeted Therapy for Renal Cell Carcinoma With Brain Metastasis

The use of targeted agents in the multimodal treatment of patients with RCC and brain metastasis was not associated with excessive neurologic adverse events. Clear cell histology, favorable MSKCC risk status, and solitary brain metastasis are associated with more favorable OS.